Have you or your loved ones been diagnosed with dermatomyositis?

You may be eligible to participate in a dermatomyositis clinical trial.

Have you or your loved ones been diagnosed with dermatomyositis? You may be eligible to participate in a dermatomyositis clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Dermatomyositis Clinical Trial
NCT04044690 | Phase 3 | Interventional
CSL Behring
Sponsored by
CSL Behring

Have you or your loved ones been diagnosed with dermatomyositis?

You may be eligible to participate in a dermatomyositis clinical trial.

Have you or your loved ones been diagnosed with dermatomyositis? You may be eligible to participate in a dermatomyositis clinical trial.

Recruiting

Male & Female

18 Years +

This study is looking to recruit 126 Participants

This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of IgPro20 subcutaneous (SC) doses in comparison to placebo in adult subjects with DM, as measured by responder status based on Total Improvement Score (TIS) assessments.